CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.
Prerna Mewawalla, MD
Advertisement
Articles by Prerna Mewawalla, MD
Advertisement
Latest Updated Articles
Managing Toxicities in BCMA/GPRC5D-Directed Therapies in Multiple MyelomaPublished: September 26th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma
2
Moving Beyond Chemotherapy in Relapsed/Refractory ES-SCLC Treatment
3
Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma
4
Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC
5
